Wall Street is positive on Zynerba Pharmaceuticals Inc (ZYNE). On average, analysts give Zynerba Pharmaceuticals Inc a Hold rating. The average price target is $1.255, which means analysts expect the stock to decrease by -1.18% over the next twelve months. That average ranking earns Zynerba Pharmaceuticals Inc an Analyst Rating of 5, which is better than 5% of stocks based on data compiled by InvestorsObserver.
Wall Street analysts are rating ZYNE a Hold today. Find out what this means to you and get the rest of the rankings on ZYNE!